ASCO 2023 - Breast Cancer

Preliminary results of the phase 2 NATASHA trial showed that neoadjuvant HER2-directed intratumoral dendritic cell vaccine therapy followed by paclitaxel, trastuzumab, and pertuzumab was well-tolerated in patients with HER2-positive breast cancer. Read More ›

The phase 1b/2 UCLA B-13 trial is evaluating the safety and efficacy of HER2 tyrosine kinase inhibitor tucatinib plus the cyclin-dependent kinase 4/6 inhibitor ribociclib and trastuzumab in the neoadjuvant setting for the treatment of patients with HER2-positive breast cancer. Read More ›

Results of the phase 2 PLEASURABLE study indicated that the chemotherapy-sparing regimen of dalpiciclib combined with pyrotinib and endocrine therapy showed significant antitumor activity for patients with estrogen receptor–positive/HER2-positive metastatic breast cancer in the front-line setting. Read More ›

Promising safety and antitumor activity data were obtained with the HER2 inhibitor ZN-1041, which is specifically designed to cross the blood-brain barrier, in preclinical and phase 1 studies in patients with HER2-positive breast cancer with brain metastases. Read More ›

Updated results of a phase 1b/2 trial showed that zanidatamab plus docetaxel as first-line therapy had a manageable safety profile and demonstrated promising antitumor activity in patients with advanced HER2-positive breast cancer. Read More ›

Real-world data from a US claims database reported similar efficacy as from a previous clinical trial in patients with previously treated HER2-positive metastatic breast cancer. Read More ›

Final results of the phase 2 ICU trial confirmed earlier reports of promising efficacy and acceptable safety of anti-HER2 antibody inetetamab in combination with camrelizumab and utidelone in patients with pretreated HER2-positive metastatic breast cancer. Read More ›

Updated results of the DAP-HER-01 trial continue to show promising efficacy and manageable toxicity with the oral chemotherapy-free dalpiciclib plus pyrotinib in patients with HER2-positive advanced breast cancer, including the difficult-to-treat subgroups of hormone receptor–negative disease or brain metastases. Read More ›

The phase 2 KAN-HER2 MRD trial will evaluate the addition of neratinib to standard trastuzumab emtansine in patients with HER2-positive breast cancer and evidence of molecular residual disease. Read More ›